Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer

Affiliations

• ¹ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: nicholas.nickols@va.gov.
• ² VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
• ³ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
• ⁴ VA Long Beach Healthcare System, Long Beach, CA, USA.
• ⁵ Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA.
• ⁶ Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
• ⁷ Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
• ⁸ Department of Radiation Oncology, Loyola University and Hines VA Medical Center, Chicago, IL, USA.
• ⁹ Cancer Research and Biostatistics, Seattle, WA, USA.
• ¹⁰ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
• ¹¹ VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.